



Ascendis Pharma A/S Announces Presentations for TransCon™ hGH at Upcoming Medical Conferences

April 21, 2021

COPENHAGEN, Denmark, April 21, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced presentations featuring TransCon hGH (lonapegsomatropin) at two upcoming medical conferences: Pediatric Endocrinology Nursing Society (PENS) national conference, taking place virtually April 21-23, and the Pediatric Endocrine Society (PES) annual meeting, taking place virtually April 30 – May 3, 2021.

“We look forward to presenting the latest data on lonapegsomatropin, our investigational once-weekly growth hormone, at PENS and PES, two of the leading medical conferences focused on pediatric endocrinology,” said Mark Bach, M.D., Ph.D., Senior Vice President of Endocrine Medical Sciences at Ascendis Pharma.

“We will present the two-year follow-up data for lonapegsomatropin which show durable results in children treated for pediatric growth hormone deficiency (GHD). In addition, we will present a model which can estimate the average weekly insulin-like growth factor 1 (IGF-1) level from a single IGF-1 sample in children with GHD treated with lonapegsomatropin. This tool may help physicians effectively manage patients on lonapegsomatropin therapy following regulatory approval,” continued Dr. Bach.

2021 PENS Virtual National Conference: Presentation Details

Poster Presentation	
Title	Date/Time
Continued Efficacy and Safety with up to 2 Years of Treatment with Lonapegsomatropin (TransCon hGH) in Children with GHD.	Poster Number: 6 Poster Session April 23, 2021 1:30 – 2:00 p.m. Eastern Time

2021 PES Virtual Annual Meeting: Presentation Details

Poster Presentations	
Title	Date/Time
Lonapegsomatropin (TransCon hGH) in Children with Growth Hormone Deficiency: Efficacy and Safety of up to 2 Years of Treatment.	Poster Number: 154 Poster 2 Viewing Session: Growth and GH/IGF Axis May 1, 2021 5:45- 6:45 p.m. Eastern Time
Estimating the weekly average IGF-1 from a single IGF-1 sample for children with GHD treated with lonapegsomatropin.	Poster Number: 156 Poster 2 Viewing Session: Growth and GH/IGF Axis May 1, 2021 5:45- 6:45 p.m. Eastern Time

The posters will be available on the Ascendis website under Selected Publications in the Pipeline section: <https://ascendispharma.us/pipeline/publications/>. If you are a healthcare provider who would like more information, please contact: medicalaffairs@ascendispharma.com.

About TransCon™ Technology

TransCon refers to “transient conjugation.” The proprietary TransCon platform is an innovative technology to create new therapies that are designed to optimize therapeutic effect, including efficacy, safety and dosing frequency. TransCon molecules have three components: an unmodified parent drug, an inert carrier that protects it, and a linker that temporarily binds the two. When bound, the carrier inactivates and shields the parent drug from clearance. When injected into the body, physiologic conditions (e.g., pH and temperature) initiate the release of the active, unmodified parent drug in a predictable manner. Because the parent drug is unmodified, its original mode of action is expected to be maintained. TransCon technology can be applied broadly to a protein, peptide or small molecule in multiple therapeutic areas, and can be used systemically or locally.

About Ascendis Pharma A/S

Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of patients, science and passion, the company utilizes its TransCon technologies to create new and potentially best-in-class therapies.

Ascendis Pharma currently has a pipeline of three independent endocrinology rare disease product candidates and one oncology product candidate in clinical development. The company continues to expand into additional therapeutic areas to address unmet patient needs.

Ascendis is headquartered in Copenhagen, Denmark, with additional offices in Heidelberg and Berlin, Germany, in Palo Alto and Redwood City, California, and in Princeton, New Jersey.

Please visit www.ascendispharma.com (for global information) or www.ascendispharma.us (for U.S. information).

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis' future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis' plans to present follow-up data for lonapegsomatropin and a model to estimate the weekly average IGF-1 level from a single IGF-1 sample in children with GHD treated with lonapegsomatropin, (ii) Ascendis' ability to apply its platform technology to build a leading, fully integrated biopharmaceutical company, (iii) Ascendis' product pipeline and expansion into additional therapeutic areas and (iv) Ascendis' expectations regarding its ability to utilize its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: unforeseen safety or efficacy results in its oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or other development programs; unforeseen expenses related to the development and potential commercialization of its oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or other development programs, selling, general and administrative expenses, other research and development expenses and Ascendis' business generally; delays in the development of its oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or other development programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; dependence on third party manufacturers to supply study drug for planned clinical studies; Ascendis' ability to obtain additional funding, if needed, to support its business activities and the effects on its business from the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis' business in general, see Ascendis' Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on March 10, 2021 and Ascendis' other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future in-licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.

*Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma Group.
© April 2021 Ascendis Pharma A/S.*

Investor contacts:

Tim Lee
Ascendis Pharma
(650) 374-6343
tlee@ascendispharma.com

Media contact:

Ami Knoefler
Ascendis Pharma
(650) 739-9952
ack@ascendispharma.com

Patti Bank
Westwicke Partners
(415) 513-1284
patti.bank@westwicke.com
ir@ascendispharma.com



Source: Ascendis Pharma